XML 49 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Gross-to-Net Product Sales and Significant Customers (Tables)
 12 Months Ended
Dec. 31, 2018
Revenues [Abstract]  
Reconciliation of Gross to Net Product Sales
The below table presents a GTN revenue (see Note 2(i)) product sales reconciliation for the accompanying Consolidated Statement of Operations:
 
Year Ended December 31,

2018

2017

2016
Gross product sales
$
190,825





$
245,797





$
244,770




Commercial rebates and government chargebacks
(68,976
)

(36.1
)%

(105,148
)

(42.8
)%

(98,317
)

(40.2
)%
Data and distribution fees, GPO fees, and inventory management fees
(14,048
)

(7.4
)%

(20,083
)

(8.2
)%

(14,979
)

(6.1
)%
Prompt pay discounts
(1,553
)

(0.8
)%

(1,610
)

(0.7
)%

(755
)

(0.3
)%
Product returns
(1,782
)

(0.9
)%

(2,778
)

(1.1
)%

(2,123
)

(0.9
)%
Product sales, net
$
104,466


54.7
 %

$
116,178


47.3
 %

$
128,596


52.5
 %
Schedule of Revenue by Major Customers by Reporting Segments
The below table presents the customers that represent 10% or more of our gross product sales in 2018, 2017, and 2016:
 
Year Ended December 31,
 
2018
 
2017
 
2016
McKesson Corporation and its affiliates
69,320

 
36.3
%
 
76,363

 
31.1
%
 
75,952

 
31.0
%
AmerisourceBergen Corporation, and its affiliates
$
55,576

 
29.1
%
 
$
79,362

 
32.3
%
 
$
93,951

 
38.4
%
Cardinal Health, Inc. and its affiliates
42,074

 
22.0
%
 
64,634

 
26.3
%
 
58,780

 
24.0
%
All other customers
23,855

 
12.5
%
 
25,438

 
10.3
%
 
16,087

 
6.6
%
Gross product sales
$
190,825

 
100.0
%
 
$
245,797

 
100.0
%
 
$
244,770

 
100.0
%
The below table presents our license fees and service revenue by source for the years ended December 31, 2018, 2017, and 2016:
 
Year Ended December 31,

2018

2017

2016
Out-license of ZEVALIN: recognition of milestone achievement, upfront cash receipt and subsequent royalties for Asia and certain other territories, excluding China (Note 12)
$
2,001


41.1
%

$
1,245


10.2
%

$
1,756


9.8
%
Out-license of FOLOTYN in all countries except the United States, Canada, Europe, and Turkey: royalties (Note 16)
1,860


38.2
%

5,848


48.0
%

927


5.2
%
Out-license of ZEVALIN, FOLOTYN, BELEODAQ, MARQIBO: upfront cash receipt and subsequent royalties for the Canada territory (Note 17(b)(xv))
1,006


20.7
%

5


—
%

6,000


33.6
%
Out-license of ZEVALIN: amortization of upfront cash receipt related to India territory (Note17(b)(iii)) and other
—


—
%

50


0.4
%

69


0.4
%
Sales and marketing contracted services (Note 14)
—


—
%

4,747


38.9
%

9,096


51.0
%
Regulatory services provided to licensee
—


—
%

294


2.4
%

—


—
%
License fees and service revenues
$
4,867


100.0
%

$
12,189


100.0
%

$
17,848


100.0
%